|  |
| --- |
| **Metabolic Pathway Enrichment in PDAC Patients Treated with Gemcitabine (Data Pooled from TCGA)** |
| **Disease Stage** | **Pathway** | **Pathway Database** | **Enrichment Score for Clinical Progressive Disease** | **Enrichment Score for Complete Response** | ***P* Value** |
| Stage 2 | DNA Replication | KEGG | 0.915 (n=25) | 0.634 (n=17) | 0.034 |
| All | DNA Replication | KEGG | 0.897 (n=29) | 0.677 (n=22) | 0.013 |
| Stage 2 | Pyrimidine NucleosideBiosynthetic Process | GOBP | 0.834 (n=25) | 0.691 (n=17) | 0.013 |
| All | Pyrimidine NucleosideBiosynthetic Process | GOBP | 0.831 (n=29) | 0.687 (n=22) | 0.016 |
| Stage 2 | Pyrimidine NucleotideBiosynthetic Process | GOBP | 0.819 (n=25) | 0.701 (n=17) | 0.024 |
| All | Pyrimidine NucleotideBiosynthetic Process | GOBP | 0.816 (n=29) | 0.706 (n=22) | 0.026 |
| Stage 2 | Glutamine Metabolic Process | GOBP | 0.864 (n=25) | 0.792 (n=17) | 0.819 |
| All | Glutamine Metabolic Process | GOBP | 0.862 (n=29) | 0.765 (n=22) | 0.630 |
| Stage 2 | Glutathione Metabolism  | KEGG | 0.931 (n=25) | 0.905 (n=17) | 0.542 |
| All | Glutathione Metabolism | KEGG | 0.970 (n=29) | 0.891 (n=22) | 0.260 |
| All | ARENRF2 Pathway | BioCarta | 0.892 (n=25) | 0.835 (n=17) | 0.488 |
| All | ARENRF2 Pathway | BioCarta | 0.903 (n=29) | 0.747 (n=22) | 0.146 |